RxDoctor Payments Data

Jin Moo Lee, MD

Neurology · Saint Louis, MONPI 1366460008

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Genentech, Inc. accounts for 90.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in MO, where the typical reported total is $933.

$187in general payments, 2019–2025

Across 2 payments — averaging $93.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$170
  • Jazz Pharmaceuticals Inc.$18
$292,726in research payments, 2019–2025

Across 69 payments — averaging $4242.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$151K
  • Genentech, Inc.$61K
  • E.r. Squibb & Sons, L.L.C.$58K
  • Abbott$23K

What the payments were for

  • Food & beverage$187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.1$170
Jazz Pharmaceuticals Inc.1$18

How this compares

$187 in reported general payments places this provider in the 30th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$8,256
Medicare patients
46
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levetiracetam22$312

Paid to pharmacies, not to this prescriber.

Other neurology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →